Biocon Chief Complains Of India Trial Delays Forcing Moves Abroad
This article was originally published in PharmAsia News
The head of Biocon is threatening to conduct more of its clinical trials in other countries despite the expense, complaining of increasingly longer delays in India's approval process.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.